$17.52-0.13 (-0.74%)
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Fortrea Holdings Inc. in the Healthcare sector is trading at $17.52 with a market capitalization of $1.5B. Wall Street consensus targets $16.39 (11 analysts), implying a -6.4% move over the next 12 months. The stock is currently near its 52-week high of $18.67, remaining 38.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $636.50M↓ | $660.50M↓ | $701.30M↓ | $710.30M↑ | $651.30M |
| Gross Profit | $123.60M↓ | $131.10M↑ | $122.70M↓ | $133.50M↑ | $116.50M |
| Operating Income | $3.30M↓ | $8.80M↑ | -$3.70M↑ | -$10.90M↑ | -$24.80M |
| Net Income | -$23.60M↑ | -$32.50M↓ | -$15.90M↑ | -$374.90M↑ | -$562.90M |
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...
Check out the companies making headlines yesterday:
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.6% in the morning session after Barclays raised its price target on the company's shares to $18 from $16, while maintaining an Equal Weight rating.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.